Arrowhead Pharmaceuticals (ARWR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.52

Estimate

-$1.50

Surprise

-1.2%

Revenue (period 2026-09-30)

$37.8M

Score today

5.6/10

Revenue source: xbrl.

Arrowhead Pharmaceuticals (ARWR) reported a wider loss than forecast — adjusted EPS of -$1.52 against the -$1.50 estimate (a 1.2% shortfall).

• Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results — fiscal.ai, 2026-11-12
• Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate — benzinga, 2026-11-12
• Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test — benzinga, 2026-11-11

TrendMatrix currently rates ARWR Sell at 5.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -1.2% surprise compares with a +41.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$47.15

Price target

$92.84

Stop

$45.06

Upside to target

+96.9%

Reward-to-risk

7.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$6.64B

P/E (fwd)

-9.5

52-week range

$37.06–$95.49

Off 52-week high

50.6%

RSI (14)

25

Volume vs avg

1.14×

Score today

5.6/10